Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Uberla

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
MMW, Munchener Medizinische Wochenschrift|February 24, 1984
[Data protection in the field of public health]K K Uberla, P L Reichertz, F W Schwartz
Haemostasis|January 1, 1980
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumonK Breddin, D Loew, K Lechner, et al.
Journal of the American Academy of Dermatology|April 1, 1997
Maternal smoking during pregnancy and lactation increases the risk for atopic eczema in the offspringT Schäfer, P Dirschedl, B Kunz, et al.
Methods of Information in Medicine|April 1, 1989
A user-oriented protocol for integrating heterogeneous communication systems of medical facilities using portsL Gierl, R Greiller, T Landersdorfer, et al.
Human Gene Therapy|March 4, 2000
Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virusT Schnell, P Foley, M Wirth, et al.
Thrombosis and Haemostasis|February 28, 1979
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective studyK Breddin, D Loew, K Lechner, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|January 1, 1996
[Munich public health education. Experiences, graduates, public health physicians]S Schneeweiss, R Weitkunat, T Abel, et al.
Immunology Today|December 1, 1990
Tumor cell targeted cytokine (TNF-alpha) gene therapy for cancerT Blankenstein, Z Qin, K Uberla, et al.
Journal of Virology|November 13, 1998
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaquesP Ten Haaft, B Verstrepen, K Uberla, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitorsB Schmidt, K Korn, B Moschik, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
MMW, Munchener Medizinische Wochenschrift|February 24, 1984
[Data protection in the field of public health]K K Uberla, P L Reichertz, F W Schwartz
Haemostasis|January 1, 1980
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumonK Breddin, D Loew, K Lechner, et al.
Journal of the American Academy of Dermatology|April 1, 1997
Maternal smoking during pregnancy and lactation increases the risk for atopic eczema in the offspringT Schäfer, P Dirschedl, B Kunz, et al.
Methods of Information in Medicine|April 1, 1989
A user-oriented protocol for integrating heterogeneous communication systems of medical facilities using portsL Gierl, R Greiller, T Landersdorfer, et al.
Human Gene Therapy|March 4, 2000
Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virusT Schnell, P Foley, M Wirth, et al.
Thrombosis and Haemostasis|February 28, 1979
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective studyK Breddin, D Loew, K Lechner, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|January 1, 1996
[Munich public health education. Experiences, graduates, public health physicians]S Schneeweiss, R Weitkunat, T Abel, et al.
Immunology Today|December 1, 1990
Tumor cell targeted cytokine (TNF-alpha) gene therapy for cancerT Blankenstein, Z Qin, K Uberla, et al.
Journal of Virology|November 13, 1998
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaquesP Ten Haaft, B Verstrepen, K Uberla, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitorsB Schmidt, K Korn, B Moschik, et al.
Pageof 12